Emerald Advisers’s BioAge Labs BIOA Stock Holding History

Emerald Advisers’s Portfolio BIOA Stock Details BIOA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-281,317	Closed	-$5.85M	–	278
2024 Q3	$5.85M	Buy	+281,317	New	+$5.64M	0.23%	108

Other funds holding BIOA

AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Emerald Advisers's BIOA Position: Q4 2024 in Review

Emerald Advisers sold out of BioAge Labs (BIOA) in Q4 2024, closing a stake of 281,317 shares — an estimated $5.85M sold.

Emerald Advisers first reported a position in BIOA in Q3 2024 and held it in 1 quarter. The position peaked at $5.85M in Q3 2024. 65 funds tracked by Wall St. Rank hold BIOA as of Q4 2024.

Emerald Advisers reported no remaining BioAge Labs position as of Q4 2024 after selling out during the quarter.
Emerald Advisers sold 281,317 BioAge Labs shares in Q4 2024, an estimated $5.85M.
Emerald Advisers first reported a position in BioAge Labs in Q3 2024 and held it in 1 quarter.
Emerald Advisers's BioAge Labs position peaked at $5.85M in Q3 2024.
65 funds tracked by Wall St. Rank held BioAge Labs as of Q4 2024.

Based on Emerald Advisers's 13F filing for Q4 2024, filed 11 Feb 2025.